Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-5584.14%
operating margin TTM
-5946.76%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -17.73 |
| peg ratio | 7.89 |
| price to book ratio | 14.47 |
| price to sales ratio | 993.39 |
| enterprise value multiple | -17.45 |
| price fair value | 14.47 |
profitability ratios | |
|---|---|
| gross profit margin | 29.09% |
| operating profit margin | -5946.76% |
| pretax profit margin | -5577.4% |
| net profit margin | -5584.14% |
| return on assets | -40.85% |
| return on equity | -98.94% |
| return on capital employed | -47.0% |
liquidity ratio | |
|---|---|
| current ratio | 10.22 |
| quick ratio | 10.12 |
| cash ratio | 3.81 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 514.57 |
| operating cycle | 734.25 |
| days of payables outstanding | 676.63 |
| cash conversion cycle | 57.63 |
| receivables turnover | 1.66 |
| payables turnover | 0.54 |
| inventory turnover | 0.71 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.33 |
| debt equity ratio | 0.65 |
| long term debt to capitalization | 0.39 |
| total debt to capitalization | 0.39 |
| interest coverage | -46.34 |
| cash flow to debt ratio | -1.00 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.04 |
| cash per share | 4.66 |
| operating cash flow per share | -2.02 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -1.00 |
| short term coverage ratios | -104.42 |
| capital expenditure coverage ratio | -98.06 |
Frequently Asked Questions
When was the last time Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) reported earnings?
Cerevel Therapeutics Holdings, Inc. (CERE) published its most recent earnings results on 08-05-2024.
What is Cerevel Therapeutics Holdings, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)'s trailing twelve months ROE is -98.94%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Cerevel Therapeutics Holdings, Inc. (CERE) currently has a ROA of -40.85%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CERE's net profit margin stand at?
CERE reported a profit margin of -5584.14% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CERE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 10.22 in the most recent quarter. The quick ratio stood at 10.12, with a Debt/Eq ratio of 0.65.